• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Mechanism of action of a bisabolol derivative and its clinical application

Research Project

Project/Area Number 16K10591
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Digestive surgery
Research InstitutionNagoya University

Principal Investigator

KOKURYO TOSHIO  名古屋大学, 医学部附属病院, 講師 (60378023)

Co-Investigator(Kenkyū-buntansha) 梛野 正人  名古屋大学, 医学系研究科, 教授 (20237564)
横山 幸浩  名古屋大学, 医学系研究科, 寄附講座教授 (80378091)
山口 淳平  名古屋大学, 医学部附属病院, 助教 (00566987)
Project Period (FY) 2016-04-01 – 2019-03-31
Project Status Completed (Fiscal Year 2018)
Budget Amount *help
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Keywordsビサボロール / 誘導体 / 胆管癌
Outline of Final Research Achievements

Bisabolol derivative suppressed proliferation, motility and invasion and induced cell death in human pancreatic cancer cell lines. Gene analysis revealed that the expression of focal adhesion kinase (FAK) in cancer cell lines was decreased by bisabolol treatment. In addition, bisabolol derivative and bisabolol significantly inhibited the tumor growth in a mouse xenograft tumor model. Bisabolol demonstrated a similar antitumor effect to that of gemcitabine upon application of a novel drug delivery system using capsules. Although bisabolol was measured in rat blood using a mass spectrograph, the pharmacokinetics of the drug was not evaluated. Further investigations will be required for clinical applications. However, this study suggests that novel therapies using bisabolol for treating refractory cancer could be efficacious.

Academic Significance and Societal Importance of the Research Achievements

本研究により、ビサボロール、ビサボロール誘導体による抗腫瘍効果およびその作用機序としてのFAK(Focal adhesion kinase)の関与を明らかにした。新たな知見が明らかになっただけでなく、治療薬としての臨床応用の可能性を明らかにしており、本研究成果の学術的、社会的意義は大きい。

Report

(4 results)
  • 2018 Annual Research Report   Final Research Report ( PDF )
  • 2017 Research-status Report
  • 2016 Research-status Report
  • Research Products

    (1 results)

All 2018

All Presentation (1 results) (of which Int'l Joint Research: 1 results)

  • [Presentation] 2-Hydroxypropyl-beta-cyclodextrin encapsulated α-bisabolol (CD-BSB) improves the antitumor effect of α-bisabolol for pancreatic cancer2018

    • Author(s)
      Taisuke Baba, Toshio Kokuryo , Yukihiro Yokoyama, Junpei Yamaguchi, Masato Nagino
    • Organizer
      the AACR’s fifth Pancreatic Cancer Special Conference: Advances in Science and Clinical Care
    • Related Report
      2018 Annual Research Report
    • Int'l Joint Research

URL: 

Published: 2016-04-21   Modified: 2023-12-25  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi